Protalex, Inc. (PRTX)
Stock Price: $0.0076 USD
0.0000 (0.00%)
Updated Jan 7, 2021 9:30 AM EST - Market closed
| Market Cap | 473 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.65M |
| Shares Out | 47.33M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 7 |
| Last Price | $0.0076 |
| Previous Close | $0.0000 |
| Change ($) | 0.0000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.0003 - 0.0076 |
| Day's Volume | 0 |
| 52-Week Range | 0.0001 - 0.0100 |
News
There are no news available yet.
About PRTX
Protalex focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of pati... [Read more...]
| Industry Drug Manufacturers - Other | IPO Date Jan 11, 2000 |
| Stock Exchange OTCMKTS | Ticker Symbol PRTX |